辰欣药业股份有限公司

Cisen Fnamaceutica Co., Ltd.

CERTIFICATE OF ANALYSIS

Product: Fludarabine Phosphate for Injection Report No.: 0000211089

Batch No.: 210405 Date of Manufacture: 04/2021

Strength: 50mg Date of Expiry: 04/2024

Package: 1 vial/box Batch Quantity: 1880 Vial

Reference Standard: Chp2020

Reference Standard. Chp2020				
Items	Acceptance criteria	Results	Conclusions	
Description	A white mass or power.	A white mass	Conform	
		or power.	Comorni	
Identification	Meet the requirement	Conform	Conform	
Acidity	pH 7.2-8.2	7.6	Conform	
Clarity and color of	Meet the requirement	Conform	Conform	
solution				
Related substances I	impurity I NMT 1.0%(corrected)	0.41%	Conform	
Related substances I	impurity II NMT 0.2%(corrected)	ND	Conform	
Related substances I	Impurity (the relative retention time is	ND	Conform	
	about 0.42) NMT 0.4% (corrected)			
Related substances I	any other Impurity NMT 0.2%	0.075%	Conform	
Related substances II	impurity III NMT 0.2%(corrected)	0.014%	Conform	
Related substances II	Impurity (the relative retention time is	0.0041%	Conform	
	about 1.9) NMT 0.2%(corrected)			
Related substances II	any other impurity NMT 0.2%	0.027%	Conform	
Total impurity	Total impurity (include Related substances			
	I and Related substances II) NMT 2.0	0.55%	Conform	
	(corrected)			
Water	Not more than 5.0%	2.6%	Conform	

Product: Fludarabine Phosphate for Injection Report No.: 0000211089

Batch No.: 210405

Strength: 50mg

Package: 1 vial/box

Date of Manufacture: 04/2021

Date of Expiry: 04/2024

Batch Quantity: 1880 Vial

Reference Standard: Chp2020

Items	Acceptance criteria	Results	Conclusions
Bacterial endotoxin	not more than 0.1EU per mg of	Conform	Conform
	Fludarabine Phosphate.		
Sterility	Meet the requirement	Conform	Conform
Weigh Variation	±10%	Conform	Conform
Visible particles	Meet the requirement	Conform	Conform
Particulate matter	≥10µm ≤6000 particles/vial;	Conform	Conform
Particulate matter	≥25µm ≤600 particles/vial	Conform	Conform
Assay	95.0%- 105.0%	98.6%	Conform

Conclusion: Conforms to the requirements of Chp2020

Remarks:

Approved by: Ren Zelin